Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline.

× No keyword cloud information.

10 in total

1. Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.

Authors: Yanxi Han; Rui Zhang; Guigao Lin; Kuo Zhang; Jiehong Xie; Jinming Li
Journal: Oncologist Date: 2017-07-12

2. Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece.

Authors: George Gourzoulidis; Oresteia Zisimopoulou; Nadia Boubouchairopoulou; Christina Michailidi; Chrissy Lowry; Charalampos Tzanetakos; Georgia Kourlaba
Journal: J Health Econ Outcomes Res Date: 2022-02-17

3. Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.

Authors: Ales Ryska; Rares Buiga; Albena Fakirova; Izidor Kern; Włodzimierz Olszewski; Lukas Plank; Sven Seiwerth; Erika Toth; Eri Zivka; Christiane Thallinger; Christoph Zielinski; Luka Brcic
Journal: Oncologist Date: 2018-08-03

4. Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice.

Authors: Kang-Yi Su; Jau-Tsuen Kao; Bing-Ching Ho; Hsuan-Yu Chen; Gee-Cheng Chang; Chao-Chi Ho; Sung-Liang Yu
Journal: Sci Rep Date: 2016-08-02 Impact factor: 4.379

5. Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: a systematic review and meta-analysis.

Authors: Yu Yang Soon; Balamurugan Vellayappan; Jeremy Chee Seong Tey; Cheng Nang Leong; Wee Yao Koh; Ivan Weng Keong Tham
Journal: Oncotarget Date: 2017-09-18

6. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.

Authors: Henri B Wolff; Elisabeth M P Steeghs; Zakile A Mfumbilwa; Harry J M Groen; Eddy M Adang; Stefan M Willems; Katrien Grünberg; Ed Schuuring; Marjolijn J L Ligtenberg; Bastiaan B J Tops; Veerle M H Coupé
Journal: JCO Precis Oncol Date: 2022-07

7. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors: SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244

8. PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines.

Authors: Jun Bie; Xin Hu; Mi Yang; Xianwei Shi; Xinping Zhang; Ziwei Wang
Journal: Hum Cell Date: 2020-01-01 Impact factor: 4.374

9. The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations.

Authors: Ming-Szu Hung; Jr-Hau Lung; Yu-Ching Lin; Yu-Hung Fang; Meng-Jer Hsieh; Ying-Huang Tsai
Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889

10. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.

Authors: Tomohiro Kondo; Junichi Matsubara; Pham Nguyen Quy; Keita Fukuyama; Motoo Nomura; Taro Funakoshi; Keitaro Doi; Yuichi Sakamori; Masahiro Yoshioka; Akira Yokoyama; Masashi Tamaoki; Tadayuki Kou; Kenshiro Hirohashi; Atsushi Yamada; Yoshihiro Yamamoto; Sachiko Minamiguchi; Masakazu Nishigaki; Takahiro Yamada; Masashi Kanai; Shigemi Matsumoto; Manabu Muto
Journal: Cancer Sci Date: 2020-11-21 Impact factor: 6.518

10 in total